

**MATERIALS LICENSE**

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 37, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee	In accordance with letter dated <b>December 16, 2014,</b>
1. Henry Ford Wyandotte Hospital	3. License number 21-12930-01 is amended in its entirety to read as follows:
2. 2333 Biddle Avenue Wyandotte, MI 48192	4. Expiration date October 31, 2015
	5. Docket No. 030-02140 Reference No.

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license
A. Any byproduct material permitted by 10 CFR 35.100	A. Any	A. As needed
B. Any byproduct material permitted by 10 CFR 35.200	B. Any	B. As needed
C. Any byproduct material permitted by 10 CFR 35.300	C. Any	C. 1 curie
D. Any byproduct material permitted by 10 CFR 31.11	D. Prepackaged kits	D. 5 millicuries
E. Iodine-125 as permitted by 10 CFR 35.400	E. Sealed sources (AmershamHealth or Medi-Physics, Inc., Model 6711 OncoSeed <sup>TM</sup> )	E. 500 millicuries

9. Authorized Use:
- A. Any uptake, dilution and excretion study permitted by 10 CFR 35.100.
  - B. Any imaging and localization study permitted by 10 CFR 35.200.
  - C. Any diagnostic or therapy procedure permitted by 10 CFR 35.300.
  - D. In vitro studies.
  - E. Any manual brachytherapy procedure permitted by 10 CFR 35.400.

**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**

License Number  
21-12930-01

Docket or Reference Number  
030-02140

Amendment No. 43

CONDITIONS

10. Licensed material shall be used at the licensee's facilities at 2333 Biddle Avenue, Wyandotte, Michigan.
11. The Radiation Safety Officer for this license is **Alan M. Jackson, M.S., CHP.**
12. Licensed material is only authorized for use by, or under the supervision of:
- A. Individuals permitted to work as an authorized user in accordance with 10 CFR 35.13 and 35.14.
- B. The following individuals are authorized users for medical uses:

Authorized Users

Material and Use

James J. Kochkodan, M.D.	10 CFR 35.100, 35.200 and 31.11.
K. D. Bartold, M.D.	10 CFR 35.100, 35.200 and 35.300.
Sharon Helmer, M.D.	10 CFR 35.100, 35.200 and 35.300.
Sophia Roumanis, M.D.	10 CFR 35.100, 35.200 and 35.300.
Jerry W. Drake, M.D.	10 CFR 35.100, 35.200 and 35.300.
Reza Abghari, M.D.	10 CFR 35.100, 35.200, 35.300 and 31.11.
David S. Yates, M.D.	10 CFR 35.100, 35.200, 35.300 (excluding iodine-131 for hyperthyroidism and cardiac dysfunction) and 31.11.
Dong Hyuck Kim, M.D.	10 CFR 35.100, 35.200 and 31.11.
John H. Finger, M.D.	10 CFR 35.100, 35.200 and 35.300.
Daniel B. Schumaker, M.D.	10 CFR 35.100, 35.200, 35.300 and 31.11.
Donald J. Conn, M.D.	10 CFR 35.100, 35.200 and 35.300.
Rob Allen Reed, M.D.	10 CFR 35.100, 35.200 (excluding generators and xenon-133).
Deepak Pradhan, M.D.	10 CFR 35.400.
Bruno F. Borin, D.O.	10 CFR 35.100 and 35.200.

**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**License Number  
21-12930-01Docket or Reference Number  
030-02140

Amendment No. 43

Vito A. Casano, M.D. 10 CFR 35.100 and 35.200.

Michael F. Zydek, M.D. 10 CFR 35.100 and 35.200.

Ibrahim Aref, M.D. 10 CFR 35.400.

**Michael Arsenault, D.O. 10 CFR 35.100, 35.200 and 35.300.**

**Kevin J. Berlin, D.O. 10 CFR 35.200.**

**Charles Terrell Cash, III, M.D. 10 CFR 35.100, 35.200 and 35.300 (limited to the oral administration of sodium iodide I-131 in any quantity.)**

**Jessica Marie Kaniowski, M.D. 10 CFR 35.100, 35.200 and 35.300 (limited to the oral administration of sodium iodide I-131 in any quantity).**

**Kevin Arthur Kearney, M.D. 10 CFR 35.100, 35.200 and 35.300 (limited to the oral administration of sodium iodide I-131 in any quantity).**

**Ronald Joseph Meade, M.D. 10 CFR 35.100, 35.200 and 35.300 (limited to the oral administration of sodium iodide I-131 in any quantity).**

**Gerling Sauter, M.D. 10 CFR 35.100, 35.200 and 35.300.**

13. The licensee is authorized to transport licensed material only in accordance with the provisions of 10 CFR Part 71, "Packaging and Transportation of Radioactive Material."


**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**License Number  
21-12930-01Docket or Reference Number  
030-02140

Amendment No. 43

14. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.
- A. Application dated March 29, 2005 (excluding references to authorized medical physicists, senior health physicist and assistant RSO); and,
- B. Letters dated April 11, 2005, October 14, 2005, and **December 16, 2014 (with attachments, excluding all references to a proposed new location of use in Brownstown Township, Michigan, and proposed authorized users Ronald Joseph Meade, M.D., and David James Rossow, M.D.)**.

  
FOR THE U.S. NUCLEAR REGULATORY COMMISSIONDate MAR 16 2015

By

  
Colleen Carol Casey  
Materials Licensing Branch  
Region III